{'fraction_non_alphanumeric': 0.015544041450777202, 'fraction_numerical': 0.0034542314335060447, 'mean_word_length': 5.51685393258427, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Premenstrual Syndrome and Spironolactone

Summary: A double blind placebo controlled randomized cross over study was conducted to assess the response to spironolactone by patients suffering from ‘Premenstrual Syndrome’. Somatic and neurophyschiatric symptoms were self‐assessed daily and a total score was calculated for each symptom for the 14 days prior to menstruation. No significant difference was noted for the symptoms assessed on or off spironolactone. The levels of oestradiol, progesterone and prolactin showed no changes from the first to the second half of the cycle.